Clinical Trial Update: A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing MEDI4736 (durvalumab) after concurrent chemoradiation in stage III unresectable non-small cell lung cancer has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-01-30